| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8440866 | European Journal of Cancer | 2016 | 7 Pages |
Abstract
We confirmed in real-world practice that SU and PZ have similar efficacy in the first-line setting for mRCC and do not affect outcomes with subsequent second-line treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jose Manuel Ruiz-Morales, Marcin Swierkowski, J. Connor Wells, Anna Paola Fraccon, Felice Pasini, Frede Donskov, Georg A. Bjarnason, Jae-Lyun Lee, Hao-Wen Sim, Andrzej Sliwczynsk, Aneta Ptak-Chmielewska, Zbigniew Teter, Benoit Beuselinck, Lori A. Wood,